OTC · CIK 0001054102
IDXG INTERPACE BIOSCIENCES, INC.
Insider trading from SEC Form 4. Last filing Aug 20, 2026.
In brief
INTERPACE BIOSCIENCES, INC. (IDXG) has 11 SEC Form 4 filings on file from 8 insiders, the latest filed on Aug 20, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at INTERPACE BIOSCIENCES, INC., scored.
Transactions
Every row filed, 27 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | Thomas W. Burnell CEO, President & Chairman | MOption exercise Common Stock | +1,966,763 | $0.00 | $0 | 2,037,645 | Aug 20, 2026 |
| Aug 20, 2026 | Christopher McCarthy CFO & COO | MOption exercise Common Stock | +277,009 | $0.00 | $0 | 323,800 | Aug 20, 2026 |
| Aug 20, 2026 | Stephen J Sullivan director | AGrant or award Restricted Stock Unitsderivative | +69,252 | $0.00 | $0 | 69,252 | Aug 20, 2026 |
| Aug 20, 2026 | Joseph D Keegan director | AGrant or award Restricted Stock Unitsderivative | +69,252 | $0.00 | $0 | 69,252 | Aug 20, 2026 |
| Aug 20, 2026 | Fortunato R. Rocca director | AGrant or award Restricted Stock Unitsderivative | +69,252 | $0.00 | $0 | 69,252 | Aug 20, 2026 |
| Aug 20, 2026 | Vijay Aggarwal director | AGrant or award Restricted Stock Unitsderivative | +69,252 | $0.00 | $0 | 69,252 | Aug 20, 2026 |
| Aug 20, 2026 | Thomas W. Burnell CEO, President & Chairman | FTax withholding Common Stock | -581,718 | $1.61 | $937k | 1,455,927 | Aug 20, 2026 |
| Aug 20, 2026 | Christopher McCarthy CFO & COO | AGrant or award Restricted Stock Unitsderivative | +554,018 | $0.00 | $0 | 554,018 | Aug 20, 2026 |
| Aug 20, 2026 | Christopher McCarthy CFO & COO | MOption exercise Restricted Stock Unitsderivative | -277,009 | $0.00 | $0 | 277,009 | Aug 20, 2026 |
| Aug 20, 2026 | Thomas W. Burnell CEO, President & Chairman | AGrant or award Restricted Stock Unitsderivative | +1,966,763 | $0.00 | $0 | 1,966,763 | Aug 20, 2026 |
| Aug 20, 2026 | Christopher McCarthy CFO & COO | AGrant or award Stock Option (right to buy)derivative | +277,009 | $0.00 | $0 | 277,009 | Aug 20, 2026 |
| Aug 20, 2026 | Thomas W. Burnell CEO, President & Chairman | MOption exercise Restricted Stock Unitsderivative | -1,966,763 | $0.00 | $0 | 0 | Aug 20, 2026 |
| Aug 20, 2026 | Thomas W. Burnell CEO, President & Chairman | AGrant or award Stock Option (right to buy)derivative | +554,018 | $0.00 | $0 | 554,018 | Aug 20, 2026 |
| Jan 20, 2026 | 1315 Capital II, L.P. owner | CConversion Common Stock | +9,405,941 | $2.02 | $19M | 9,405,941 | Feb 17, 2026 |
| Jan 20, 2026 | 1315 Capital II, L.P. owner | CConversion Series C Convertible Preferred Stockderivative | -19,000 | $0.00 | $0 | 0 | Feb 17, 2026 |
| Jan 20, 2026 | Ampersand 2018 Limited Partnership owner | CConversion Common Stock | +13,861,386 | $2.02 | $28M | 13,861,386 | Feb 4, 2026 |
| Jan 20, 2026 | Ampersand 2018 Limited Partnership owner | CConversion Series C Convertible Preferred Stockderivative | -28,000 | $0.00 | $0 | 0 | Feb 4, 2026 |
| Jul 31, 2023 | Christopher McCarthy Chief Financial Officer | MOption exercise Common Stock | +7,556 | $0.00 | $0 | 15,872 | Apr 25, 2025 |
| Dec 1, 2023 | Christopher McCarthy Chief Financial Officer | MOption exercise Common Stock | +1,095 | $0.00 | $0 | 16,967 | Apr 25, 2025 |
| Jan 31, 2024 | Christopher McCarthy Chief Financial Officer | MOption exercise Common Stock | +7,556 | $0.00 | $0 | 24,523 | Apr 25, 2025 |
| Feb 1, 2024 | Christopher McCarthy Chief Financial Officer | MOption exercise Common Stock | +6,045 | $0.00 | $0 | 30,568 | Apr 25, 2025 |
| Jul 27, 2024 | Christopher McCarthy Chief Financial Officer | MOption exercise Common Stock | +15,112 | $0.00 | $0 | 45,680 | Apr 25, 2025 |
| Dec 1, 2024 | Christopher McCarthy Chief Financial Officer | MOption exercise Common Stock | +1,111 | $0.00 | $0 | 46,791 | Apr 25, 2025 |
| Oct 11, 2024 | 1315 Capital II, L.P. owner | DDisposition to issuer Series B Convertible Preferred Stockderivativeindirect: See Footnotes | +19,000 | - | - | 0 | Oct 15, 2024 |
| Oct 11, 2024 | Ampersand 2018 Limited Partnership owner | DDisposition to issuer Series B Convertible Preferred Stockderivativeindirect: See Footnotes | +28,000 | - | - | 0 | Oct 15, 2024 |
| Oct 11, 2024 | 1315 Capital II, L.P. owner | AGrant or award Series C Convertible Preferred Stockderivativeindirect: See Footnotes | +19,000 | - | - | 19,000 | Oct 15, 2024 |
| Oct 11, 2024 | Ampersand 2018 Limited Partnership owner | AGrant or award Series C Convertible Preferred Stockderivativeindirect: See Footnotes | +28,000 | - | - | 28,000 | Oct 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- 1315 Capital II, L.P.owner
- Vijay Aggarwaldirector
- Ampersand 2018 Limited Partnershipowner
- Thomas W. BurnellCEO, President & Chairman
- Joseph D Keegandirector
- Christopher McCarthyCFO & COO
- Fortunato R. Roccadirector
- Stephen J Sullivandirector
Questions about IDXG
Answered from the filings on this page, as of the latest one.
Are insiders buying IDXG?
No. In the last 90 days no insider at INTERPACE BIOSCIENCES, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade IDXG on the open market?
No open-market trade has been scored at INTERPACE BIOSCIENCES, INC.. The latest Form 4 on file was filed on Aug 20, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at INTERPACE BIOSCIENCES, INC.?
8 people have filed a Form 4 at INTERPACE BIOSCIENCES, INC., among them 1315 Capital II, L.P. (10% owner), Vijay Aggarwal (director), Ampersand 2018 Limited Partnership (10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.